Floatz logo

Bind-014

KRAS Positive Patients With Non-small Cell Lung Cancer

BIND TherapeuticsPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the KRAS Positive Patients With Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
BIND 014
BIND Therapeutics
Phase 2B

Same molecule, other indications

Bind-014 is also rated in:

CRPCDormant
B
Indicative ·
57 / 100
View asset →
Squamous Cell Non-small Cell Lung CancerDormant
B
Indicative ·
57 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →